′ -phosphate-dependent enzyme that catalyses the production of the neurotransmitters dopamine and serotonin. Among the so far identified mutations associated with AADC deficiency, an inherited rare neurometabolic disease, the S250F mutation is the most frequent one. Here, for the first time, the molecular basis of the deficit of the S250F variant was investigated both in vitro and in cellular systems. Ser250 is not essential for the catalytic activity of the enzyme. However, its mutation to Phe causes a ∼7-fold reduction of catalytic efficiency and a conformational change in the proximity of the mutated residue that is transmitted to the active site. In cellular extracts of E. coli and mammalian cells, both the specific activity and the protein level of the variant decrease with respect to the wild-type. The results with mammalian cells indicate that the mutation does not affect intracellular mRNA levels, and are consistent with a model where S250F undergoes a degradation process via the proteasome, possibly through an ubiquitination process occurring faster than in the wild-type. Overall, biochemical and cell biology experiments show that loss of function of S250F occurs by two distinct but not exclusive mechanisms affecting activity and folding. Importantly, 4-phenylbutirric acid (4-PBA) or, to a major extent, pyridoxine increase the expression level and, in a dose-dependent manner, the decarboxylase specific activity of mutant-expressing cells. This strongly suggests that 4-PBA and/or pyridoxine administration may be of important value in therapy of patients bearing the S250F mutation.
INTRODUCTION
Aromatic amino acid decarboxylase (AADC) deficiency, a rare neurometabolic disorder, is a loss-of-function disease whose symptoms are directly related to the absence of functional dopa decarboxylase (DDC), a pyridoxal 5 ′ -phosphate (PLP)-dependent enzyme responsible for the production of the neurotransmitters dopamine and serotonin. More than 50 patients with DDC deficiency have been tabulated on the BIOMDB database (http://www.biopku.org/biomdb/biom db_start.asp), and 23 missense pathogenic mutations have been identified, half of which in homozygous patients. Although the clinical phenotype associated with the disease has been widely investigated (1, 2) , the molecular effect(s) that any mutation induces on DDC is almost unknown.
Nonsense and frameshifts mutations lead to the complete loss of the gene product, while missense point mutations cause the synthesis of an aberrant gene product which can be characterized by defects of enzymatic activity, PLP binding, protein stability and/or folding, protein half-life, etc. Current treatments for AADC deficiency are the administration of pyridoxine or PLP to increase the residual DDC activity, or MAO-B inhibitors to minimize the dopamine degradation or dopamine agonists to mime the action of the neurotransmitter (3) . The response to these therapies is variable, but the overall outcome is rather poor, probably reflecting the allelic heterogeneity. Moreover, since drugs are almost always given in combination, response is hardly ascribable to a single drug. In diseases related to protein malfunction, it is diagnostically and therapeutically essential to understand the † The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors. * To whom correspondence should be addressed at: Department of Life Sciences and Reproduction (Section of Biological Chemistry), University of Verona (Italy) Strada Le Grazie, 8, 37134 Verona, Italy. Tel: +39 0458027175; Fax: +39 0458027179; Email: carla.borrivoltattorni@univr.it multiple mechanisms that relate the specific mutants with the pathology. Therefore, the knowledge of the structural and/or functional effect(s) that each amino acid substitution produces on DDC would be highly desirable. A first example of this approach is a recent study in which, by means of biochemical and bioinformatic analyses, the molecular defects of four recombinant purified pathogenic variants whose mutations concern residues located at or near the active site have been identified. On these bases, a therapeutic treatment has also been proposed (4) . In the present work, we tried to understand the structural and/or functional defects of the S250F variant, the most common one associated with AADC deficiency (1,5 -7) . A combination of biochemical analyses on the purified recombinant protein paired with expression studies using a well-characterized mammalian tissue culture cell line [Chinese hamster ovary (CHO) cells] has been used. From our investigations, it can be deduced that the S250F mutation causes both catalytic and folding defects consisting in a reduction in catalytic activity and an enhanced susceptibility to degradation mediated by the proteasome pathway. Importantly, 4-phenylbutirric acid (4-PBA) and, to a major extent, pyridoxine partially rescue the functionality of the variant. This suggests that these molecules may be of value in therapy of patients bearing the S250F mutation.
RESULTS

Expression studies of S250F variant in E. coli
Decarboxylase assays and western blotting analyses of crude cellular extracts of E. coli reveal that the specific activity and the immunoreactivity of the S250F variant are 14 and 66%, respectively, of the corresponding ones of the wild-type (Table 1) . Although these data confirm the pathogenicity of S250F mutation, they do not allow the identification of the mechanism(s) producing the enzyme malfunction. In fact, the low specific activity appears to be due not only to the drop of the expression yield, but also to the decrease in the catalytic activity of the mutant. Since the expression in E. coli offers the possibility to produce and purify sufficient quantities of the S250F variant for detailed structural and functional analyses, we followed this approach in order to elucidate the molecular basis of the deficit of the S250F variant.
Biochemical studies of recombinant purified S250F
The purified S250F variant is homogeneous as indicated by a single band on SDS PAGE with a mobility identical to that of wild-type human DDC. The equilibrium dissociation constant value for PLP, [K D(PLP) ] of the variant (62 + 24 nM) does not significantly change when compared with that of the wild-type [43 + 12 nM (4)]. This is consistent with the fact that Ser250, belonging to the large domain of DDC, is located at 12 Å from PLP. However, several lines of evidence indicate that substitution of Ser by Phe at position 250 alters the PLP binding mode and microenvironment. First, while wild-type human DDC displays two absorbance bands centred at 420 and 335 nm with a ratio A 335nm /A 420nm of 2 (4), these bands in the S250F variant show a lower intensity and a 3-nm blue shift with a ratio A 417nm /A 332nm of 1.5 ( Fig. 1) . Second, although the absorbance bands of both wild-type and mutant are associated with positive dichroic bands, the magnitudes of the 420 nm dichroic signal of wild-type and variant are identical, while that of the 332 nm band of the variant is about half with respect to that of the wild-type (inset of Fig. 1) . Thus, the wild-type and S250F enzymes display optical activity (mdeg/absorbance unit) values of 54 and 32 mdeg/A 420 and of 102 and 59 mdeg/A 335 , respectively. Third, upon excitation at 335 nm, the NaBH 4 -reduced S250F mutant exhibits a decreased emission fluorescence intensity at 390 nm with respect to wildtype DDC (Fig. 2) . Again, as shown in the inset of Figure 2 , the reduced variant, when excited at 280 nm, displays a decreased energy transfer efficiency between tryptophan residues(s) and the reduced coenzyme. Phenylalanine at position 250 might perturb the active site directly through unfavourable electrostatic or steric interactions with PLP or indirectly by inducing conformational changes in the vicinity of the mutation site. The latter possibility may be favoured on the basis of the following data of the mutant compared with the corresponding ones of the wild-type: (i) a consistent decrease in the 280-nm optically active band (inset of Fig. 1 ), (ii) a reduction in the intrinsic fluorescence emission intensity accompanied by a 2-nm blue shift of the emission maximum (Fig. 3A) and (iii) an increase in aniline-1-naphtalenelsulphonic acid (ANS) fluorescence emission intensity and a shift of the emission maximum from 479 to 475 nm (Fig. 3B) . However, circular dichroism (CD) spectra taken in the far-UV region were practically superimposable for wild-type and S250F variant, indicating no gross alterations in the secondary structure (data not shown). Moreover, the profile and the kinetics of limited proteolysis of the variant were identical to those of wild-type DDC (data not shown). Finally, dynamic light scattering (DLS) measurements indicate that S250F has a hydrodynamic diameter of 10 nm, identical to that of the wild-type. This value is consistent with either that derived from the crystal structure of pig kidney DDC (9.5 nm) (8) or that calculated by an appropriate empirical equation (7 + 2 nm) (9) .
The steady-state turnover and apparent K m values of L-dopa for the wild-type and S250F mutant enzymes have been compared (Table 2) . At pH 7.4 and 258C, the k cat value of the variant drops by a factor of 3.5, while the K m value increases by a 2-fold factor, resulting in a 7-fold reduction of the catalytic efficiency. Thus, taking into account the k cat value of the variant in comparison with that of the wild-type, it could be deduced that the true specific activity of the S250F variant in the crude cellular extracts of E. coli is 49% that of the wild-type.
Like the apo wild-type, the apo variant does not display absorbance and CD bands in the visible region. However, in comparison with the apo wild-type, a modest reduction in the magnitude of the dichroic signal in the near UV region, in the intensity of the intrinsic fluorescence emission and in the ANS emission intensity can be detected in the apo variant (data not shown).
To understand if the S250F mutation has an impact on the thermostability of the holo and/or apo forms of the variant, their thermal inactivation kinetics has been examined at 378C over a period of 3 h and compared with that of the wildtype (Fig. 4) . No loss of decarboxylase activity of the holo forms of both wild-type and variant has been observed. In contrast, we detected a time-dependent apoS250F-inactivation more consistent than that of the apo wild-type. This would indicate that the apoS250F at physiological temperature is more susceptible to inactivation than the apo-wild-type.
Molecular modelling
To rationalize how Ser250 replacement with Phe could affect the DDC structure, we performed a molecular modelling study based on the crystal structure of pig kidney holo DDC (8) . This structure might be a good model, being the overall degree of identity with human DDC equal to 88.7%. Ser250 belongs to the loop 243 -252 with the stretch 243 -246 facing the active site and the stretch 247-252 facing the surface of the molecule. The Og of Ser250 is in a proper position to form an H-bond interaction with the Og of Thr245. Figure 5 shows the superimposition of the active site of the solved DDC structure with the putative one of the S250F variant obtained by energy minimization means. In the variant the Phe250 side chain is predicted to be oriented toward the protein surface and to possibly make an hydrophobic interaction with Phe215. Thus, the Ser-to-Phe substitution could not only destabilize the conformation of the loop 243 -252, as a consequence of the loss of the H-bond between Ser250 and Thr245, but also alter the chemical features of the DDC surface that is predicted to become more hydrophobic.
S250F variant: cell biology analyses in a cellular system
To ascertain whether the replacement of Ser250 with Phe affects the functional features of DDC in a mammalian cellular system, wild-type and variant were transiently expressed in CHO cells. The specific activity and the expression level of the S250F mutant were 14 and 30% (Fig. 6 ), respectively, of those of wild-type DDC ( Table 1 ). Considering that the S250F mutation causes an 70% reduction in the k cat value of the purified recombinant enzyme, the decreased specific activity in CHO cells can be ascribed partly to the reduced catalytic activity and partly to the low expression level of the variant.
As a first step, we checked if the difference in the protein expression levels between wild-type DDC and the S250F variant was due to a varied transfection efficiency or to a different mRNA intracellular stability. No differences in the levels of mRNA for wild-type DDC and the S250F variant were observed, as revealed by the amount of the encoding transcripts quantified by real-time PCR (data not shown). Therefore, the low mutant expression appears to be due to a failure at the protein level rather than at the transcriptional level, thus suggesting that the S250F mutation could affect the folding process and/or the susceptibility of DDC to intracellular degradation. Nevertheless, the finding that the relative amounts of soluble and insoluble protein recovered from lysates of CHO cells expressing wild-type and mutant DDC are similar indicates that the mutation does not make DDC prone to intracellular aggregation, which is consistent with the data obtained with the purified protein. Thereafter, we measured the half-life of wild-type and mutant DDC by cycloheximide chase assays. As shown in Figure 7A -C, the S250F mutation decreases the DDC half-life in CHO cells from 19 + 1 to 11+ 1 h, thus suggesting that the variant could be more susceptible than wild-type DDC to intracellular degradation. To have insights about the mechanism of degradation, cycloheximide chase assays have been carried out in the presence of the lysosome inhibitor, chloroquine, or the proteasome inhibitor, MG132. Chloroquine does not change the half-life of the two enzymatic species, while MG132 partly slows down protein degradation. However, this effect is higher for the variant than for the wild-type ( Fig. 7A-C ). These data mean that (i) the DDC turnover inside the cell is partly mediated by the proteasome instead of the lysosome pathway, and (ii) the mutation makes DDC more susceptible to proteasomal degradation. On these bases, since poly-ubiquitination is an important process for targeting proteins to proteasome, we investigated whether S250F is more susceptible than wild-type DDC to ubiquitination. CHO cells transiently expressing wild-type DDC or the S250F variant were immunoprecipitated with antibodies against ubiquitin and subsequently immunoblotted with the anti-DDC antibody. The results shown in Supplementary Material, Fig. S1A and B, show that while no signal is detected, as expected, in CHO cells transfected with the empty vector, a broad smear pattern typical of the poly-ubiquitin-conjugated DDC is observed in cells expressing wild-type and mutant. It should be noticed that, even if the smear pattern prevents a precise densitometric analysis, the signal relative to the mutant is higher than that relative to wild-type DDC. These data indicate that DDC is conjugated to ubiquitin prior to proteasomal degradation and corroborate the idea that the S250F variant is more prone to degradation upon poly-ubiquitination.
Following these results, we investigated the effects of pyridoxine, a precursor of PLP used in the clinical practice for patients with inherited diseases associated with deficit of PLP enzymes, and of some compounds (betaine and 4-PBA) known to act as small-molecule chaperones on the expression level and the specific activity of wild-type and mutant DDC transiently expressed in CHO cells. As shown in Figure 8A , while betaine does not affect the expression of wild-type and mutant DDC, either pyridoxine or 4-PBA increase the expression level of both enzymatic species. Accordingly, the results reported in Figure 8B indicate that: (i) pyridoxine increases the specific activity measured in CHO cells expressing wildtype or S250F variant, but the change is statistically significant only in the case of the variant, (ii) pyridoxine plus betaine or 4-PBA significantly increase the specific activity detected in cells expressing wild-type, and, to a major extent, that of cells expressing the pathogenic variant, (iii) pyridoxine plus betaine has an effect on the specific activity of CHO cells expressing wild-type and mutant, which is not significantly different from that of pyridoxine alone, which is consistent with the null effect of betaine. The increase in the specific activity of the S250F variant is dependent on vitamin B6 or 4-PBA concentration, reaching its maximum at 10 mM pyridoxine and 1 mM 4-PBA (Fig. 8B) Taken together, the results obtained in the CHO cellular model system allow us to conclude that (i) the S250F mutation causes a structural defect in DDC that makes the protein more susceptible to intracellular degradation and (ii) pyridoxine or 4-PBA are able to rescue for the effect of the mutation by increasing the expression level and specific activity of the variant.
DISCUSSION
Several diseases mainly of neurological and metabolic origin are associated with inherited mutations of genes encoding PLP-enzymes (10) (11) (12) . AADC deficiency is a rare neurometabolic disorder whose molecular bases are poorly understood. Since the S250F mutation is the most frequent one being present in one-tenth of all reported cases of patients with AADC deficiency, we decided to investigate the molecular basis of this mutation both in vitro and in cellular systems.
Steady-state kinetic parameters of the purified recombinant S250F variant show that the mutation does not involve a residue essential for catalytic activity, since it only causes a 7-fold reduction of the catalytic efficiency. Although the far-UV and DLS data exclude any gross alteration in the conformation of the S250F variant, the finding that the variant has an intrinsic fluorescence emission spectrum, a CD spectrum in 
the near-UV region and ANS binding properties different from the corresponding ones of the wild-type suggests that it has a slightly altered tertiary structure. Moreover, S250F has a perturbed active site, as can be inferred from the altered absorbance and CD bands of the bound PLP and the decreased intensity of the coenzyme emission of the NaBH 4 -reduced protein.
An explanation for all these data is that the mutation at position 250 of Ser to Phe possibly induces a conformational change in the proximity of the mutation site that is transmitted to the active site. According to the computational analysis, substitution to Phe predictably (i) breaks a hydrogen bond between Ser250 and Thr245, an interaction which could be important to stabilize the loop 243-252, (ii) causes an altered mobility of this loop due to the bulky side chain of Phe and (iii) enhances the hydrophobic surface of the enzyme. Although the information derived from the molecular modelling of the S250F variant is of course not an experimental evidence, it is not in contrast with the in vitro data. Based on these results, one can consider S250F a catalytic mutation. However, DDC assays and western immunoblot analyses of the crude cellular extracts of E. coli and of CHO cells transiently expressing wild-type or S250F variant indicate, in addition to a reduced specific activity, a decreased amount of immunoreactive S250F protein with respect to wild-type. This implies that the molecular defect of the S250F variant does not only rely on the decreased catalytic activity of the protein compared with wild-type DDC, but also on a decreased expression level that exacerbates the molecular defect responsible for the decreased specific activity of the variant. It should be noted that the reduced protein level caused by the mutation in the mammalian cellular milieu is (i) not produced by differences at the level of transcription since the intracellular mRNA levels are not decreased, and (ii) not ascribable to intracellular protein aggregation because the relative amounts of soluble and insoluble S250F are comparable with those of the wild-type. The latter finding is in agreement with the fact that DLS measurements do not reveal any aggregation propensity of recombinant S250F. Instead, considering that the half-life drops from 19 h for the wild-type to 11 h for the S250F, it is reasonable to suggest that the variant is expressed in cells but is degraded faster than the wild-type. We have also shown that the degradation of wild-type and mutant depends, at least in part, on the activity of the proteasome instead of the lysosome pathway. Indeed, MG132 does not completely block protein degradation, thus suggesting that other proteolytic pathways could contribute to DDC turnover, as already proposed for other proteins (13) . Remarkably, MG132 preserves from the degradation process more efficiently the S250F variant than the wild-type, and ubiquitination is more pronounced in the S250F variant than in the wild-type. Ubiquitination is often driven by conformational changes and/or order -disorder transition since unstructured region or newly exposed surface of the target protein is recognized by ubiquitin ligase. Indeed, the S250F mutation generates a conformational change that possibly leads to a more hydrophobic surface (as indicated by ANS experiments, and predicted by molecular modelling). Altogether, these data reinforce the view that the reduction in the S250F protein level might be ascribable to its degradation by the proteasomal pathway, and allow us to advance that the mutation might affect the folding pathway leading to accumulation of denatured and/or partially denatured forms of the variant prone to proteolytic degradation. It has been already reported that mis-or unfolded proteins are usually processed by cellular degradation pathways (14) .
For this reason, small-molecule chaperones, which could help to improve the folding of S250F variant, have been tested. Exposure of mutant-expressing CHO cells to betaine does not affect the specific activity and immunoreactivity of the variant. In contrast, 4-PBA at 1 mM concentration raises the specific activity of the variant to 34% of wild-type, a good improvement over the specific activity (15%) of this mutant under non-treated cells. Notably, 4-PBA is of clinical use in the treatment of patients affected by cystic fibrosis bearing the DF508 responsible for a folding defect (15) . Quite intriguing is the effect of pyridoxine, a PLP precursor, which results to be more effective than 4-PBA since at 10 mM concentration increases the specific activity to 60% of wild-type. The effect of pyridoxine and/or PLP, even if at a variable degree of responsiveness, has already been demonstrated for some inborn errors associated with PLP-dependent enzymes: 90% in d-aminolevulinate synthase deficiency, 50% in cystathionine b-synthase deficiency, 10-30% in alanine glyoxylate aminotransferase and 5% in ornithine d-aminotransferase deficiency (10, 16) . For some patients, the obvious explanation could be that they carry mutations that impair the PLP binding to the enzyme. However, since the mutation site in some pyridoxine-responsive patients makes this explanation unlike (10, 17) , it has already been proposed that PLP could assist protein folding, thus reducing the likelihood of degradation of misfolded proteins (18 -20) . This appears to be the case for the S250F variant associated with AADC deficiency. A question remains to be elucidated: is the chaperoning activity of pyridoxine exerted on the apo or the holo form of the variant? Some conclusions can be drawn from our data and literature. Cell biology studies provided evidence that the apo form of rat liver DDC is degraded in PC12 cells faster than the holo form (21) . The structural basis of this behaviour has been recently related to the striking difference between the crystal structure of apo- (22) and holo-DDC (8) . At physiological temperature, while the S250F mutation does not affect the kinetic stability of the holo form of the variant, it causes a time-dependent more significant inactivation of the apo variant compared with that of the apo wild-type. The inactivation, not dependent on the protein concentration and not accompanied by generation of aggregates, presumably originates from an enhanced amount of denatured and/or misfolded forms of the apovariant in comparison with the apowild-type. Based on these in vitro results, the hypothesis could be advanced that in vivo the coenzyme plays a prosthetic role shifting from the less stable apo to the more stable holo form, thus preventing the degradation process. However, several lines of evidence argue against this view. First, since, on the basis of the medium composition, the pyridoxine concentration in CHO cells is 0.3 mM, and both the apo forms of wild-type and variant exhibit a K D(PLP) value of 50 nM, both these enzymatic species should be mainly in the holo form. Second, the effect of pyridoxine on the variant is not limited to an increase in the specific activity but also in the expression level. Third, the effect of pyridoxine observed in CHO cells is dose-dependent, reaching its maximum at a concentration 200-fold higher than the K D(PLP) .
On these bases, it can be proposed that pyridoxine could act as a pharmacological chaperone on the holo form of the S250F variant. Such a role has been already raised for tyrosine aminotransferase (18) and alanine glyoxylate aminotransferase folding (19, 20) . For both these enzymes, a degradation via a proteasome pathway has been reported (18, 23) . This is the first study in which the molecular basis of the AADC deficiency has been elucidated by a combination of biochemical and cell biology analyses. This approach allowed us to highlight that the S250F mutation results in catalytic and folding effects, thus confirming its pathological involvement and paving the way for the implementation of a useful tailored treatment. The yet undescribed chaperoning effect of pyridoxine on the S250F variant may be useful in patients bearing this mutation as well as other mutations associated with AADC deficiency giving rise to structural defects.
MATERIALS AND METHODS
Materials
PLP, L-dopa, 2,4,6-trinitrobenzene-1-sulfonic acid, isopropylb-D-thiogalactopyranoside, protease inhibitor cocktail, betaine, pyridoxine hydrochloride and 4-PBA were purchased from Sigma. ANS was purchased from Molecular Probes. The polyclonal goat anti-DDC (C-16), the anti-ubiquitin antibody and the anti-glyceraldehyde 3 ′ -phosphate dehydrogenase (GAPDH) antibody were purchased from Santa Cruz Biotechnology, from AbCam and from Millipore, respectively. All other chemicals were of the highest purity available.
Expression constructs
The full-length cDNA coding for human DDC cloned on a pCMV-XL5 vector (pCMV-DDC) was purchased from Origine Technologies and cloned on a pTrcHis2A vector to give the construct pDDChis as previously described (4). The S250F mutation was inserted into the pDDChis and pCMV-DDC expression vectors by the QuikChange II sitedirected mutagenesis kit (Stratagene) using the 1620 Human Molecular Genetics, 2013, Vol. 22, No. 8
′ and its complement (the mutated codon is underlined). The mutation was confirmed by DNA sequencing.
Protein purification and determination of the coenzyme equilibrium dissociation constant Purification of his-tagged wild-type DDC and of the S250F variant was performed following the procedure previously described (4). Protein concentration was determined using the 1 M ¼ 142 000 M 21 cm 21 at 280 nm. The PLP content of the S250F variant was determined by releasing the coenzyme in 0.1 M NaOH and by using 1 M ¼ 6600 M 21 cm 21 at 388 nm. For the apoenzyme preparation, the S250F variant was incubated with 5 mM hydroxylamine in 0.5 M potassium phosphate buffer, pH 6.9 at 258C for 3 h and the mixture was loaded on a desalting 26/10 column (GE Healtcare) pre-equilibrated with the same buffer without hydroxylamine (24) .
The equilibrium dissociation constant for PLP, K D(PLP) , from the S250F variant was determined by measuring the quenching of the intrinsic fluorescence of the apoenzyme (0.1 mM) in the presence of PLP at a concentration range of 0.01-10 mM in 100 mM potassium phosphate buffer, pH 7.4 and by fitting the data to the following equation:
where [E] t and [PLP] t represent the total concentrations of the enzyme and PLP, respectively, Y refers to the intrinsic quenching changes at a PLP concentration, [PLP] , and Y max refers to the aforementioned changes when all enzyme molecules are complexed with coenzyme.
Enzyme activity assays
The decarboxylase activity toward L-dopa of wild-type DDC and the S250F variant in the purified form was measured by the spectrophotometric assay described by Sherald et al. (25) , and modified by Charteris and John (26) . Measurements were performed in the presence of 100 mM PLP in 100 mM potassium phosphate buffer, pH 7.4. Data of enzymatic activity as a function of substrate concentration were fitted to the Michaelis -Menten equation. The effect of PLP on thermostability of the apo form of wild-type and mutant was measured as follows: wild-type (0.2 mM) or S250F (0.5 mM) either in the holo or apo form was incubated in 100 mM phosphate buffer, pH 7.4, at 378C. Aliquots were withdrawn at various times, and, after incubation with 10 mM PLP for 10 min, assayed as above described.
The DDC decarboxylase activity toward L-dopa in the soluble fraction of cellular lysates of CHO cells was determined through HPLC analysis (27) . Thirty micrograms of 
Human Molecular Genetics, 2013, Vol. 22, No. 8 1621 cell lysate were incubated in 100 mM potassium phosphate buffer pH 7.4 at 258C in the presence of 2 mM L-dopa and 10 mM PLP. After 30 min (a time within which a linear product formation is observed) the reaction was stopped by adding trichloracetic acid to a final concentration of 10% (v/v). After centrifugation to remove precipitated proteins, the supernatants were analysed using a Supelcosyl C18 (250 × 4.6 mM) (Supelco) column connected to a Jasco PU-2080 Plus HPLC control system. The eluent was 50 mM potassium phosphate buffer, pH 2.35, at flow rate of 1 ml/min. A Jasco UV-2075 Plus detector set at 280 nm was employed for dopamine detection. Peaks corresponding to dopamine eluting at 9 min were integrated with Jasco Borwin software. A standard curve of peak area as function of dopamine concentration was prepared using commercially available dopamine.
Spectroscopic measurements
Absorption measurements were performed with a Jasco V-550 spectrophotometer at a protein concentration of 5 mM. Fluorescence spectra were recorded with a FP750 Jasco spectrofluorimeter using 5 nm excitation and emission bandwidths at a protein concentration of 0.1 -1 mM. CD measurements were made with a Jasco J-710 spectropolarimeter at a protein concentration of 5 mM. All the spectroscopic measurements were carried out in 100 mM potassium phosphate buffer, pH 7.4, at 258C. DLS analyses were performed on a ZetasizerNano S instrument (Malvern Instruments) by using disposable 12.5 × 45-mm cells with stopper (20) . Wild-type DDC and S250F variant were diluted to 4 mM concentration in 60 mM potassium phosphate buffer, pH 7.4 in the presence of 20 mM PLP. The temperature was kept at 37 + 0.18C during the measurements by a Peltier temperature controller.
Limited proteolysis
DDC wild-type and S250F variant at 10 mM enzyme concentration were treated with proteinase K at a 1/50 (w/w) protease to enzyme ratio in 100 mM potassium phosphate buffer, pH 7.4, at 258C in the presence of 20 mM PLP. At various times, 15 ml aliquots were withdrawn and the reaction was stopped by addition of PMSF to a final concentration of 2 mM. Samples were analysed by SDS PAGE. After staining with Coomassie brilliant blue, the band intensities were visualized and analysed using ImageJ software (Wajne Rasband).
Molecular modelling analysis
The structural model of the S250F mutant was generated starting from the pig kidney crystal structure of DDC in complex with PLP (pdb file 1JS6). Protonation state assignment and local energy minimization were performed setting a protein and solvent dielectric constant of 2.0 and 80.0, respectively, a pH value of 7.4, a ionic strength of 150 mM, and a temperature of 378C. For all calculation, the force field adopted was AMBER99. The analysis was performed using the Molecular Operating Environment software (CCG group).
Cell culture, transfection and lysis CHO cells were cultured at 378C under O 2 /CO 2 (19:1) atmosphere in Ham's F12 Glutamax medium (Invitrogen) supplemented with foetal bovine serum (10%,v/v), penicillin (100 units/ml) and streptomycin (100 mg/ml), as previously described (28) . Cell transfection was performed using the Turbofect TM Transfection Reagent (Fermentas) according to the manufacturer's instructions. After 4 h the medium containing the DNA -lyposome complex was replaced with fresh complete Ham's F12 medium. Cells were harvested after 24 h and pellets were stored at 2808C until lysis. The effect of pyridoxine, betaine, and 4-PBA was tested by adding each of the compounds or their combination to the medium 4 h after transfection.
Cells were lysed in phosphate-buffered saline (PBS) plus protease inhibitor cocktail (Complete Mini, Roche) and subjected to five freeze-thaw cycles. Samples were treated with DNAse (10 U) at 378C for 45 min. The whole cell extract was separated by centrifugation (28 400g, 10 min, 48C) to obtain the soluble fraction. The pellet was then resuspended 
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in an equal volume of denaturing gel loading buffer to obtain the insoluble fraction. The total protein concentration of the soluble fraction was measured using the Bio-Rad DC TM protein assay according to the manufacturer's instructions.
Transcript expression analysis
CHO cells were grown in a 6-well plate and transfected using Turbofect (Fermentas) as described above. Cells were harvested, washed with PBS, and RNA was extracted using the RNeasy mini kit (Qiagen). The cDNA was synthetized from 1 mg of mRNA using the Supersctipt VILO cDNA synthesis kit (Invitrogen, Carlsbad, CA) according to manufacturer's instructions. Real-time PCR was performed using 3 ml of a 1:10 cDNA dilution in a 25 ml reaction volume using SYBR Premix Ex Taq master mix (TaKaRa) on a Corbett RotorGene 6000 thermocycler. The reaction conditions included initial denaturation at 958C for 15 min followed by 45 cycles of PCR which included 15 s melting at 958C, 30 s annealing at 558C and 30 s extension at 728C. The samples were examined for the expression of human DDC using the forward primer 5 ′ -GAAGGAGAGGGAAGGAGATGG-3 ′ and the reverse primer 5 ′ -GGAAGTAGGCGAAGAAGTAGG-3 ′ . The amount of the wild-type and S250F hDDC mRNA was calculated in relation to the GAPDH mRNA in the same sample. Quantitation of individual transcripts was performed using the 'Comparative Quantitation' software supplied by Corbett Research for the RotorGene. The mean efficiency of a group of cycling curves is calculated at the point that the cycling curves take off and used to calculate a fold change according to the formula: fold change ¼ efficiency Ct1 -Ct2, where Ct1 and Ct2 are the take-off values of the cycling curves being compared. All reactions were performed in duplicate.
Western blotting
Fifteen micrograms of lysate were loaded per lane on a Mini Protean TGX TM pre-cast gel (Biorad) along with Precision plus protein Kaleidoscope TM (Bio-Rad) as molecular mass markers. Following transfer on a nitrocellulose membrane by the iBlot device (Invitrogen) the membrane was blocked in 5% bovine serum albumin for 1 h at 378C. For DDC detection, the membrane was incubated with polyclonal goat anti-DDC (C-16) (Santa Cruz Biotechnology) (dilution 1:250) and peroxidase-conjugated donkey-anti-goat IgG (dilution 1:2000) as primary and secondary antibody, respectively. Blotted proteins were detected and quantified with ECL w (Millipore), using the ChemiDoc XRS Imaging System (Bio-Rad, Hercules, CA). As a gel loading control, the amount of GAPDH was determined using the mouse monoclonal antibody anti GAPDH (Millipore) (dilution 1:1000).
Pulse-chase experiments and DDC immunoprecipitation
The half-life of DDC in the wild-type and S250F mutant form was determined by treating transfected CHO cells with cycloheximide (10 mg/ml) 24 h post-transfection. After 4, 8, 12 and 24 h of cycloheximide treatment, cells were lysed and DDC levels were quantified by immunoblotting as described above. Where indicated, cells were treated with the proteasomal inhibitor, MG132 (10 mM), or the lysosome inhibitor, chloroquine (100 mM), 1 h before the addition of cycloheximide. To assess the increase in total ubiquitinated proteins, which confirms the proteasome inhibition in the presence of 10 mM MG132, CHO cell lysates were immunoblotted with the rabbit anti-ubiquitin antibody (AbCam).
To check the ubiquitination level of wild-type and S250F DDC, the soluble fraction of each cell lysate (100 mg) was incubated over night with 2 mg of rabbit anti-ubiquitin antibody (AbCam) on a rotator at 48C. Thereafter, the immunoprecipitation reaction was performed at room temperature by adding 30 ml of agarose-protein A (GE, Healthcare) to the mixture and by incubating the solution for 1 h on a rotator. The immunoprecipitated complex was collected by centrifuging at 29 200 g at 48C for 5 min, washed three times with IP wash/lysis buffer (Thermo Scientific), and resuspended in 20 ml of denaturing gel loading buffer. Proteins were separated on SDS PAGE and DDC was detected by immunoblotting as described above. Untransfected and non-immunoprecipitated DDC-transfected CHO cell lysates were used as negative and positive control, respectively.
Statistical analysis
The two-way ANOVA algorithm for repeated measures was used for data analysis. Differences with P , 0.05 were considered significant.
